The concept of patient partnerships has been extensively debated in recent years. While most would agree that patients can contribute valuable insights to the overall healthcare ecosystem, just how and where the pharma industry should champion the patient voice remains unclear.
Thanks to advancements in technology, there are more opportunities to engage patients in both clinical and home settings. As such, the potential avenues for patient partnerships and industry collaborations are increasing.
In this issue of Deep Dive, Sharon Suchotliff, associate principal at ZS Associates, details why patient centricity is more important than ever, Envision Pharma Group’s Dr Dawn Lobban and Vitaccess’ Dr Catherine Bottomley discuss ways that patients can contribute to the development and publication of real-world studies, and Erin McEachren and Syed Rashid of Johnson & Johnson explore how strategic partnerships can help to improve transparency and outcomes for vision patients.
Plus, experts from Roche consider the importance of community voices in the future of neurology care, IPSEN’s Dr Oleksandr Gorbenko and MediPaCe’s Dr Sandeep Bagga discuss co-creating a patient engagement impact framework, Lumanity’s Ann-Marie Chapman and Marieke Schurer explore how burden of illness studies can add valuable context in HTA submissions, and Research Partnership’s Mariel Metcalfe and Nicole Syms share key insights into the patient experience of endometriosis.
For all this and more, read on.
I hope you are staying safe and well.
Eloise
Eloise McLennan – editor, Deep Dive
For the best page-viewing experience, make sure you have your browser at full-screen size. Use the left/right arrow buttons to scroll through the pages or click on the menu icon bottom centre to navigate. You can also share the articles on social media by clicking the icon bottom left at the base of the main navigation or at the end of each article.
Digital Health 2022
Plus:
Catch up on recent issues:
Communications & Commercialisation – September 2021
Oncology – June 2022
Market Access – May 2022
Research and Development – February 2022